BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...three years after another deal by the Manhattan-based partners, in which the university granted Fortress’ Caelum Biosciences Inc....
BioCentury | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained...
...studies; Spector said the measure was "not studied or published by Prothena." Paul Bonanos 11-1F4, CAEL-101 Alexion Pharmaceuticals Inc. Caelum Biosciences Inc. Fortress...
BioCentury | Jan 26, 2018
Clinical News

Fortress' Caelum subsidiary reports MTD for CAEL-101 in AL amyloidosis

...The Caelum Biosciences Inc. subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) said data from a U.S. Phase Ia/Ib trial...
BioCentury | May 17, 2017
Clinical News

Fortress completes Phase I enrollment of amyloidosis candidate CAEL-101

...plans to start a Phase II trial of the chimeric fibril-reactive mAb in 1H18. Fortress' Caelum Biosciences Inc....
BioCentury | Jan 6, 2017
Company News

Columbia University, Fortress Biotech deal

...The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101...
Items per page:
1 - 5 of 5
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...three years after another deal by the Manhattan-based partners, in which the university granted Fortress’ Caelum Biosciences Inc....
BioCentury | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained...
...studies; Spector said the measure was "not studied or published by Prothena." Paul Bonanos 11-1F4, CAEL-101 Alexion Pharmaceuticals Inc. Caelum Biosciences Inc. Fortress...
BioCentury | Jan 26, 2018
Clinical News

Fortress' Caelum subsidiary reports MTD for CAEL-101 in AL amyloidosis

...The Caelum Biosciences Inc. subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) said data from a U.S. Phase Ia/Ib trial...
BioCentury | May 17, 2017
Clinical News

Fortress completes Phase I enrollment of amyloidosis candidate CAEL-101

...plans to start a Phase II trial of the chimeric fibril-reactive mAb in 1H18. Fortress' Caelum Biosciences Inc....
BioCentury | Jan 6, 2017
Company News

Columbia University, Fortress Biotech deal

...The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101...
Items per page:
1 - 5 of 5